Literature DB >> 11384702

Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants.

A H Schaap1, H Wolf, H W Bruinse, H Smolders-De Haas, I Van Ertbruggen, P E Treffers.   

Abstract

OBJECTIVE: To evaluate the effect of antenatal corticosteroids on mortality, morbidity, and disability or handicap rate in early preterm, growth-restricted infants.
METHODS: This case-control study in two tertiary care centers included all live-born singleton infants with growth-restriction due to placental insufficiency, who were delivered by cesarean because of cardiotocographic signs of fetal distress before the beginning of labor at a gestational age of 26-32 weeks during the years 1984-1991. Infants who had been treated antenatally with corticosteroids more than 24 hours and less than 7 days before birth were matched by birth weight, sex, and year of birth with infants whose mothers had been admitted more than 24 hours before delivery but were not treated antenatally with steroids. The main outcome measure was survival without disability or handicap at 2 years corrected age. A sample of 60 case-control pairs would give 81% power to demonstrate 50% increase of this outcome [odds ratio (OR) 3.0] by corticosteroid treatment. Behavior and physical growth were evaluated at school age by questionnaire.
RESULTS: The study group and control group consisted of 62 infants each. Survival without disability or handicap at 2 years' corrected age was more frequent in the corticosteroid group [OR 3.2, confidence interval (CI) 1.1, 11.2]. In the long-term follow-up at school age there was a statistically significant negative effect on physical growth (OR 5.1, CI 1.4, 23.8), but no differences in behavior were detected.
CONCLUSION: Benefits from antenatal corticosteroids for early preterm, growth-restricted infants appear to outweigh possible adverse effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384702     DOI: 10.1016/s0029-7844(01)01343-6

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

Review 1.  Antenatal corticosteroids in preterm small-for-gestational age infants: a systematic review and meta-analysis.

Authors:  Stephanie A Blankenship; Kristine E Brown; Laura E Simon; Molly J Stout; Methodius G Tuuli
Journal:  Am J Obstet Gynecol MFM       Date:  2020-08-17

Review 2.  Antenatal corticosteroids in the management of preterm birth: are we back where we started?

Authors:  Clarissa Bonanno; Ronald J Wapner
Journal:  Obstet Gynecol Clin North Am       Date:  2012-03       Impact factor: 2.844

3.  Association of Antenatal Corticosteroids With Mortality, Morbidity, and Neurodevelopmental Outcomes in Extremely Preterm Multiple Gestation Infants.

Authors:  Nansi S Boghossian; Scott A McDonald; Edward F Bell; Waldemar A Carlo; Jane E Brumbaugh; Barbara J Stoll; Abbot R Laptook; Seetha Shankaran; Michele C Walsh; Abhik Das; Rosemary D Higgins
Journal:  JAMA Pediatr       Date:  2016-06-01       Impact factor: 16.193

4.  Antenatal dexamethasone treatment leads to changes in gene expression in a murine late placenta.

Authors:  B Baisden; S Sonne; R M Joshi; V Ganapathy; P S Shekhawat
Journal:  Placenta       Date:  2007-06-07       Impact factor: 3.481

5.  The Effects of Antenatal Corticosteroids on Short- and Long-Term Outcomes in Small-for-Gestational-Age Infants.

Authors:  Hiroshi Ishikawa; Ken Miyazaki; Tomoaki Ikeda; Nao Murabayashi; Kazutoshi Hayashi; Akihiko Kai; Kaoru Ishikawa; Yoshihiro Miyamoto; Kunihiro Nishimura; Yumi Kono; Satoshi Kusuda; Masanori Fujimura
Journal:  Int J Med Sci       Date:  2015-03-20       Impact factor: 3.738

Review 6.  Antenatal Corticosteroids for Reducing Adverse Maternal and Child Outcomes in Special Populations of Women at Risk of Imminent Preterm Birth: A Systematic Review and Meta-Analysis.

Authors:  Rachel M Amiya; Linda B Mlunde; Erika Ota; Toshiyuki Swa; Olufemi T Oladapo; Rintaro Mori
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.